ACADIA Pharmaceuticals Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From ACADIA Pharmaceuticals Inc.
Gilead ups its investment in its TIGIT partner, as the firms pivot to a less crowded market opportunity in upper GI cancers.
Twelve new drugs are now being reviewed for potential EU marketing approval, including Servier’s vorasidenib for IDH-mutant diffuse glioma, which the company says could become the first targeted therapy for the malignant and incurable brain tumor.
Pipeline is concentrated around Phase II, but sponsors have a few chances to see how FDA handles its ‘foundational constructs’ for psychedelic drugs, led by Lykos’ pending NDA for PTSD and Compass Pathways’ Phase III synthetic psilocybin COMP360 for treatment-resistant depression.
10 orphan drugs imported from overseas, and 40 new drug approvals, including many from domestic developers, capped 2023 as one of the busiest years for China's drug regulatory agency, as Beijing pivoted to emphasizing affordable innovation and expanding access to newer therapies for rare conditions.
- Other Names / Subsidiaries
- Receptor Technologies
- CerSci Therapeutics
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.